On Monday, Shares of Weatherford International Plc (NYSE:WFT), lost -1.31% to $9.76.
Weatherford International, stated a net loss before charges of $77 million ($0.10 net loss per share non-GAAP) on revenues of $2.39 billion for the second quarter of 2015. GAAP net loss for the second quarter of 2015 was $489 million, or a net loss of $0.63 per share.
Second Quarter 2015 Highlights
- Positive free cash flow of $104 million, principally on improved working capital performance and lower capital expenditures;
- Free cash flow improved sequentially $370 million, despite lower earnings; and
- Accomplished 97% of the reduction in force target of 10,000 employees by June 30, 2015, with predictable annualized savings of $686 million.
Weatherford International plc provides equipment and services used in the drilling, evaluation, completion, production, and intervention of oil and natural gas wells worldwide.
Shares of Christopher & Banks Corporation (NYSE:CBK), inclined 1.70% to $0.59, during its last trading session.
Canadian Bank Note, declared that it has attained Unicom Graphics and will integrate Unicom’s operations with CBN’s McAra Printing division to deliver exceptional print solutions for their customers. CBN has made substantial investments in new technology at McAra over the past several years and the acquisition of Unicom is a continuation of its investment in its Calgary operation.
“By combining the complementary strengths of two leading Calgary -based commercial printers, we have created a single exceptional print solutions provider. CBN is committed to providing McAra Unicom investment and technical support to successfully grow the business. ”
Ronald G. Arends, President & CEO, Canadian Bank Note Company, Limited
With this acquisition, McAra Unicom will offer high-quality lithographic print counting UV technology, digital print and wide format services, complete bindery counting perfect binding, foiling and embossing, direct mail and fulfillment. These capabilities combined with technical consultation and security services will provide customers with a unique offering.
Christopher & Banks Corporation, through its auxiliaries, operates as a retailer of women’s apparel and accessories in the United States. The company designs, sources, and sells women’s apparel and accessories to customers ranging in age from 45 to 60.
Finally, Antares Pharma Inc (NASDAQ:ATRS), ended its last trade with 2.65% gain, and closed at $1.94.
Antares Pharma, stated operating and financial results for the second quarter ended June 30, 2015. The Company stated revenue of $14.4 million and a net loss per share of $0.01 for the second quarter and revenue of $22.8 million and a net loss of $0.06 per share for the first half of 2015. Antares ended the second quarter with $58.1 million in cash, cash equivalents and investments and no debt.
Second Quarter 2015 and Recent Highlights
- Stated record quarterly revenues of $14.4 million counting $3.3 million in OTREXUP™ sales and $1.8 million in revenues generated from epinephrine auto injector devices sold and shipped to Teva during the second quarter.
- Declared the enrollment of the first patients in the QuickShot testosterone supplemental safety study. We believe a minimum of 70 patients will be needed to complete collection of 26 weeks of safety data.
- Raised the number of prescriptions to 8,123 and unique prescribers of OTREXUP™ (methotrexate) injection to about 1,673 physicians at the end of the second quarter as contrast to 6,722 prescriptions and about 1,546 physicians at the end of the first quarter, according to Symphony Health Solutions.
- Accomplished an underwritten public offering of 23.0 million shares of the Company’s common stock at a purchase price of $2.00 per share, resulting in net proceeds to the Company of $42.8 million.
- Designated Peter J Graham Esq. to the position of Senior Vice President, General Counsel, Human Resources, Chief Compliance Officer and Corporate Secretary.
- Declared the settlement of all litigation between Antares and Medac Pharma, Inc. and its parent medac GmbH. The settlement agreement provides for a royalty-free cross-license under the patents-in-suit for the U.S.
- Regained U.S. marketing rights to OTREXUP™ (methotrexate) injection for subcutaneous use for the psoriasis indication through the termination of an exclusive promotion and marketing agreement with LEO Pharma A/S.
Antares Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
